| Species-and site-specific genome editing in complex bacterial communities BE Rubin, S Diamond, BF Cress, A Crits-Christoph, YC Lou, AL Borges, ... Nature Microbiology 7 (1), 34-47, 2022 | 213* | 2022 |
| Temperature-responsive competitive inhibition of CRISPR-Cas9 F Jiang, JJ Liu, BA Osuna, M Xu, JD Berry, BJ Rauch, E Nogales, ... Molecular Cell 73 (3), 601-610 e5, 2019 | 78 | 2019 |
| Structural basis for AcrVA4 inhibition of specific CRISPR-Cas12a GJ Knott, BF Cress, JJ Liu, BW Thornton, RJ Lew, B Al-Shayeb, ... eLife 8, e49110, 2019 | 48 | 2019 |
| STEAP1–4 (six-transmembrane epithelial antigen of the prostate 1–4) and their clinical implications for prostate cancer M Xu, L Evans, CL Bizzaro, F Quaglia, CE Verrillo, L Li, J Stieglmaier, ... Cancers 14 (16), 4034, 2022 | 26 | 2022 |
| Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer B Dhital, S Santasusagna, P Kirthika, M Xu, P Li, M Carceles-Cordon, ... Cell Reports Medicine 4 (2), 2023 | 14 | 2023 |
| 913 Tumor immune micro-environment (TIME) Atlas for prostate cancer bone metastasis K Canubas, M Xu, W Kelly, J Marte, HA Sater, JL Gulley, W Lassoued Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Association between bispecific T cell engager (BiTE) therapy and inflammatory adverse effects (AEs) in patients with metastatic castration-resistant prostate cancer (mCRPC). M Xu, B Wummer, WK Kelly, B Bashir Journal of Clinical Oncology 41 (16_suppl), e14534-e14534, 2023 | | 2023 |
